Evidence map›Paper›PMID 42752967›Full record

ArticleDiabetologia2026

The GPCR

Marta Lopez-Balastegui, Shuangyu Lian, Wenwen Gao, Florence Gbahou, Tomasz M Stepniewski, Julie Dam, Ralf Jockers, Jana Selent

Abstract read
PubMed Publisher
In one paragraph

Article in Diabetologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marta Lopez-BalasteguiResearch Programme on Biomedical Informatics (GRIB), Hospital del Mar Research Institute (HMRIB)-Pompeu Fabra University (UPF), Barcelona, Spain.ORCID http://orcid.org/0000-0002-6283-601X
Shuangyu LianUniversité Paris Cité, Institut Cochin, Inserm, CNRS, Paris, France.ORCID http://orcid.org/0009-0004-5564-6578
Wenwen GaoUniversité Paris Cité, Institut Cochin, Inserm, CNRS, Paris, France.ORCID http://orcid.org/0009-0007-6209-0493
Florence GbahouUniversité Paris Cité, Institut Cochin, Inserm, CNRS, Paris, France.ORCID http://orcid.org/0000-0002-2795-378X
Tomasz M StepniewskiResearch Programme on Biomedical Informatics (GRIB), Hospital del Mar Research Institute (HMRIB)-Pompeu Fabra University (UPF), Barcelona, Spain.ORCID http://orcid.org/0000-0002-6828-9192
Julie DamUniversité Paris Cité, Institut Cochin, Inserm, CNRS, Paris, France. julie.dam@inserm.fr.ORCID http://orcid.org/0000-0001-6871-2678
Ralf JockersUniversité Paris Cité, Institut Cochin, Inserm, CNRS, Paris, France. ralf.jockers@inserm.fr.ORCID http://orcid.org/0000-0002-4354-1750
Jana SelentResearch Programme on Biomedical Informatics (GRIB), Hospital del Mar Research Institute (HMRIB)-Pompeu Fabra University (UPF), Barcelona, Spain. jana.selent@upf.edu.ORCID http://orcid.org/0000-0002-1844-4449

Funding

Agence Nationale de la Recherche ANR-21-CE18-0023Agence Nationale de la Recherche ANR-23-CE14-0033ERDF/EU PID2022-137161OB-I00Fondation pour la Recherche Médicale EQU202503020060French Government Initiative d'excellence - ANR-18-IDEX-0001Horizon Europe Project OBELISK 101080465
6 · The paper itself

Abstract

aims/hypothesisThe glucagon-like peptide-1 receptor (GLP1R) is a key regulator of glucose homeostasis and body weight, and a major therapeutic target for type 2 diabetes and obesity. Individual disease risk and response to treatments may vary widely depending on the presence of missense variants (MVs) in the GLP1R gene, but accurate prediction of the impact of MVs in the G protein-coupled receptor (GPCR) remains challenging. Here we aimed to generate a reliable and GPCR-tailored predictor of the impact of MVs that is applicable for precision medicine.

methodsWe developed a GPCR variant impact predictor (GPCR

resultsThe GPCR CONCLUSIONS/

interpretationThese findings establish the GPCR

Indexed as

Allosteric networksAlphaMissenseGLP-1GLP1RGPCRGPCRVPMembrane-aware modellingMissense variantsMolecular dynamicsObesityREVELType 2 diabetesVariant impact prediction

Identifiers

PMID42752967

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.